Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

298.43 +6.43 (+2.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
59 60 Next >
Should You Still Buy the Nasdaq's Best-Performing September Stocks?
Tech stocks sold off last month, but these three were gainers. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
These two healthcare stocks are reliable passive income vehicles. 
Via The Motley Fool
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX). 
Via Benzinga
Check Out What Whales Are Doing With AMGN
 
Via Benzinga
2 Dividend Growth Stocks to Buy Right Now
A wise man once said, be greedy when others are fearful. 
Via The Motley Fool
FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer
FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an... 
Via Benzinga
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
Should You Still Buy the Dow Jones' Best-Performing September Stocks?
A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy. 
Via The Motley Fool
Topics Stocks
Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns
The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ: 
Via Benzinga
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Check Out What Whales Are Doing With AMGN
 
Via Benzinga
Amgen Unusual Options Activity
 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
 
Via Benzinga
AskSlim Market Week - Friday, Sep. 29
Technical and cycle analysis, and market commentary. 
Via Talk Markets
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States. 
Via InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of... 
Via Benzinga
2 Top Dividend Stocks to Buy in September
These two blue-chip dividend stocks have stood the test of time. 
Via The Motley Fool
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
Why Shares of Neumora Therapeutics Slumped This Week
The clinical-stage biotech just had its IPO last week. 
Via The Motley Fool
Topics Initial Public Offering
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
3 Quality Dividend Stocks For A Bear Market
The potential for a recession means investors should focus on quality dividend stocks with strong yields. 
Via Talk Markets
Topics Economy
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners. 
Via InvestorPlace
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.